Ye-Qing Zhang

Ye-Qing Zhang


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2018 in Phytochemical Analysis
Verified
Journal Article
Closed access
PDF file
YZYe‐Ting Zou
Ye‐Ting Zou
FLFang Long
Fang Long
CWCheng‐Ying Wu
Cheng‐Ying Wu
JZJing Zhou
Jing Zhou
WZWei Zhang
Wei Zhang
SLSong-Lin Li
Song-Lin Li

1 May 2017 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
XLXiu-Yang Li
Xiu-Yang Li
FLFang Long
Fang Long
JXJin-Di Xu
Jin-Di Xu
HSHong Shen
Hong Shen
MKMing Kong
Ming Kong
SLSong-Lin Li
Song-Lin Li

8 October 2024 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
MDMiaomiao Di
Miaomiao Di
FNFangbing Niu
Fangbing Niu
PYPeng Yang
Peng Yang
SZShuting Zheng
Shuting Zheng
BYBingyang Yang
Bingyang Yang
FLFang Long
Fang Long

10 February 2026 in Chinese Herbal Medicines
Verified
Journal Article
Open access
TZTiantian Zhao
Tiantian Zhao
QLQi Liu
Qi Liu
XSXiangjia Song
Xiangjia Song
FLFei Liao
Fei Liao
YZYe-Qing Zhang
Ye-Qing Zhang
NZN. Zhao
N. Zhao
Community-acquired pneumonia (CAP) is a leading cause of death from infectious diseases in adults worldwide. Traditional Chinese medicine injections (TCMIs) are often used as complementary therapies. This study aimed to evaluate the efficacy and safety of TCMIs for the treatment of CAP. A step-by-step strategy was first designed including data collection, systematic review, Bayesian network meta-analysis (NMA), and assessment of the NMA. Eight databases were searched for relevant randomized clinical trials (RCTs) from their inception to December 31, 2022. The Cochrane risk-of-bias tool was used to assess the methodological quality and the risk of bias of the included RCTs. Bayesian NMA was performed by WinBUGS 14.0 and STATA 15.0. Finally, the Grading of Recommendation, Assessment, Development, and Evaluation (GRADE) system was used to evaluate the quality of evidence for each outcome. A total of 35 RCTs involving 4 291 participants were included. For clinical effectiveness rate, the Reduning Injection (RDN) combined with Western medicine (WM) was the most likely to be the best treatment (SUCRA = 0.919). And the top three TCMIs interventions were RDN + WM, Xiyanping Injection (XYP) + WM, Tanreqing injection (TRQ) + WM. For defervescence time, disappearance time of cough, and the disappearance time of lung rales, the XYP with WM was probably the best treatment (SUCRA = 0.822, 0.838, 0.816). Moreover, adverse drug reactions have been reported in 14 RCTs. The TCMIs can effectively relieve clinical symptoms and improve clinical efficiency than that of WM alone for adults with non-severe CAP. Step-by-step results firstly indicated that XYP with WM was superior treatment regimen to reduce defervescence time, disappearance time of cough and disappearance time of lung rales. For safety, the mild adverse drug reactions occurred during the entire course of therapy and were self-limiting, further confirming the favorable safety profile of the TCMIs.